Back
  1. Home
  2. Profile of Sébastien Tabruyn (ULiège)
Profil

Tabruyn Sébastien

See author's contact details
Main Referenced Co-authors
Struman, Ingrid  (33)
Martial, Joseph  (32)
Noël, Agnès  (18)
Nguyen, Ngoc-Quynh-Nhu  (15)
Halkein, Julie  (13)
Main Referenced Keywords
Humans (8); Animals (7); angiogenesis (3); Angiogenesis Inhibitors/therapeutic use (3); Mice (3);
Main Referenced Unit & Research Centers
Giga-Cancer - ULiège [BE] (3)
Giga-Signal Transduction - ULiège [BE] (1)
Main Referenced Disciplines
Biochemistry, biophysics & molecular biology (32)
Oncology (5)
Endocrinology, metabolism & nutrition (3)
Biotechnology (2)
Rheumatology (1)

Publications (total 43)

The most downloaded
429 downloads
Tabruyn, S., Colton, K., Morisada, T., Fuxe, J., Wiegand, S. J., Thurston, G., Coyle, A. J., Connor, J., & McDonald, D. M. (2010). Angiopoietin-2-Driven Vascular Remodeling in Airway Inflammation. American Journal of Pathology. doi:10.2353/ajpath.2010.100059 https://hdl.handle.net/2268/76102

The most cited

107 citations (Scopus®)

Tabruyn, S., & Griffioen, A. W. (2008). NF-kappa B: a new player in angiostatic therapy. Angiogenesis, 11 (1), 101-6. doi:10.1007/s10456-008-9094-4 https://hdl.handle.net/2268/37541

Bovy, N., Halkein, J., Martial, J., Tabruyn, S., & Struman, I. (19 May 2012). Circulating microRNAs as a new way of communication between endothelial and tumor cells [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (19 May 2012). MicroRNA-146a, a downstream effector of 16K prolactin, is a therapeutic target and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Halkein, J., Tabruyn, S., Haghikia, A., Hoch, M., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (April 2012). MicroRNA-146a is a causative factor and a specific biomarker for peripartum cardiomyopathy [Poster presentation]. Biomedica, Liège, Belgium.

Bovy, N., Halkein, J., Martial, J., Tabruyn, S., & Struman, I. (April 2012). Circulating microRNAs as a new way of communication between endothelial and tumor cells [Poster presentation]. Biomedica, Liège, Belgium.

Struman, I., Halkein, J., Tabruyn, S., Haghiskia, A., Hoch, M., Nguyen, N.-Q.-N., Malvaux, L., sliwa, K., Noël, A., Martial, J., & Hilfiker-kleiner, D. (2012). MicroRNA-146a, a downstream effector of 16kDa prolactin, impairs the endothelium-cardiomyocyte cross-talk in peripartum cardiomyopathy. In FASEB meeting:the Growth Hormone/Prolactin Family in Biology and Disease.
Peer reviewed

Halkein, J., Tabruyn, S., Haghikia, A., Castermans, K., Malvaux, L., Lambert, V., Labidi, S., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (January 2012). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Keystone symposia on Angiogenesis advances in basic sciences and therapeutic applications, Snowbird Resort, Snowbird, Utah, United States.

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (May 2011). The antiangiogenic 16K prolactin disturbs functional tumor neovascularization by affecting vessel maturation [Poster presentation]. 4th International Meeting on Angiogenesis, Amsterdam, Netherlands.

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (March 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. IVth International Meeting on Angiogenesis, Amsterdam, Netherlands.

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (March 2011). Mir-146a : A new angiostatic miRNA with tumor-suppressive properties [Poster presentation]. IVth International Meeting on Angiogenesis, Amsterdam, Netherlands.

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (February 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Keystone Symposia : MicroRNAs and Human Disease, Banff, Alberta, Canada.

Halkein, J., Bovy, N., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (February 2011). MiR-146a: an angiostatic miRNA with tumor-suppressive properties [Poster presentation]. Keystone Symposia : MicroRNAs and Non-Coding RNAs and Cancer, Banff, Alberta, Canada.

COLLIGNON, J., Struman, I., Tabruyn, S., Josse, C., Boukerroucha, M., JERUSALEM, G., & BOURS, V. (2011). Aspects moléculaires du cancer du sein triple négatif et les implications thérapeutiques. Revue Médicale de Liège, 66 (5-6), 393-396.
Peer reviewed

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Alvarez Gonzalez, M.-L., Rakic, J.-M., Noël, A., Labidi, S., Hilfiker-Kleiner, D., Martial, J., Tabruyn, S., & Struman, I. (January 2011). MiR-146a an angiostatic miRNA elevated in peripartum cardiomyopathy [Poster presentation]. Giga-Day Symposia, Liège, Belgium.

Fuxe, J., Tabruyn, S., Colton, K., Zaid, H., Adams, A., Baluk, P., Lashnits, E., Morisada, T., Le, T., O'Brien, S., Epstein, D. M., Koh, G. Y., & McDonald, D. M. (2011). Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation. American Journal of Pathology, 178 (6), 2897-909. doi:10.1016/j.ajpath.2011.02.008
Peer Reviewed verified by ORBi

Halkein, J., Castermans, K., Malvaux, L., Lambert, V., Noël, A., Martial, J., Tabruyn, S., & Struman, I. (October 2010). Mir-146a : A new angiostatic miRNA with tumor-suppressive properties [Poster presentation]. Frontiers in Tumor Progression, Madrid, Spain.

Halkein, J., Tabruyn, S., Malvaux, L., Sabatel, C., Martial, J., & Struman, I. (21 May 2010). miR-146a: an anti-angiogenic miRNA regulated by NF-kB [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Fuxe, J., Lashnits, E., O'Brien, S., Baluk, P., Tabruyn, S., Kuhnert, F., Kuo, C., Thurston, G., & McDonald, D. M. (2010). Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation. American Journal of Pathology, 176 (4), 2009-18. doi:10.2353/ajpath.2010.090976
Peer Reviewed verified by ORBi

Sabatel, C., Cornet, A., Tabruyn, S., Malvaux, L., Castermans, K., Martial, J., & Struman, I. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9 (1), 231. doi:10.1186/1476-4598-9-231
Peer Reviewed verified by ORBi

Tabruyn, S., Colton, K., Morisada, T., Fuxe, J., Wiegand, S. J., Thurston, G., Coyle, A. J., Connor, J., & McDonald, D. M. (2010). Angiopoietin-2-Driven Vascular Remodeling in Airway Inflammation. American Journal of Pathology. doi:10.2353/ajpath.2010.100059
Peer Reviewed verified by ORBi

Tabruyn, S., Memet, S., Ave, P., Verhaeghe, C., Mayo, K. H., Struman, I., Martial, J., & Griffioen, A. W. (2009). NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Molecular Cancer Therapeutics, 8 (9), 2645-54. doi:10.1158/1535-7163.MCT-09-0383
Peer Reviewed verified by ORBi

Sennino, B., Kuhnert, F., Tabruyn, S., Mancuso, M. R., Hu-Lowe, D. D., Kuo, C. J., & McDonald, D. M. (2009). Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Research, 69 (10), 4527-36. doi:10.1158/0008-5472.CAN-08-3779
Peer Reviewed verified by ORBi

Sabatel, C., Tabruyn, S., Cornet, A., Martial, J., & Struman, I. (30 March 2008). Study of the role of Sprouty1 in the regulation of angiogenesis [Poster presentation]. GIGA-Cancer Day, Liège, Belgium.

Tabruyn, S., & Griffioen, A. W. (2008). NF-kappa B: a new player in angiostatic therapy. Angiogenesis, 11 (1), 101-6. doi:10.1007/s10456-008-9094-4
Peer Reviewed verified by ORBi

Castermans, K., Tabruyn, S., Zeng, R., van Beijnum, J. R., Eppolito, C., Leonard, W. J., Shrikant, P. A., & Griffioen, A. W. (2008). Angiostatic activity of the antitumor cytokine interleukin-21. Blood, 112 (13), 4940-7. doi:10.1182/blood-2007-09-113878
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (December 2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Molecular Therapy, 15 (12), 2094-2100. doi:10.1038/sj.mt.6300294
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Gordon research on angiogenesis, Newport, United States - Rhode Island.

Verhaeghe, C., Tabruyn, S., Oury, C., Bours, V., & Griffioen, A. W. (2007). Intrinsic pro-angiogenic status of cystic fibrosis airway epithelial cells. Biochemical and Biophysical Research Communications, 356 (3), 745-749. doi:10.1016/j.bbrc.2007.02.166
Peer reviewed

Tabruyn, S., & Griffioen, A. W. (2007). Molecular pathways of angiogenesis inhibition. Biochemical and Biophysical Research Communications, 355 (1), 1-5. doi:10.1016/j.bbrc.2007.01.123
Peer reviewed

Tabruyn, S., & Griffioen, A. W. (2007). A new role for NF-kappaB in angiogenesis inhibition. Cell Death and Differentiation, 14 (8), 1393-7. doi:10.1038/sj.cdd.4402156
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., FOIDART, J.-M., Noël, A., Martial, J., & Struman, I. (2007). Inhibition of tumor growth and metastasis by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K prolactin [Poster presentation]. Keystone symposia: Host cell response to cancer, Bozeman, United States - Montana.

Sabatel, C., Tabruyn, S., Cornet, A., Griffioen, A., Martial, J., & Struman, I. (January 2007). Study of the molecular mechanisms involved in the response of tumor and host to the treatment with the antiangiogenic factor 16K prolactin [Poster presentation]. Host cell response to cancer, Keystone, United States.

Tabruyn, S., Sabatel, C., Nguyen, N.-Q.-N., Verhaeghe, Castermans, K., Malvaux, L., Griffioen, A. W., Martial, J., & Struman, I. (2007). The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Molecular Endocrinology, 21 (6), 1422-9. doi:10.1210/me.2007-0021
Peer Reviewed verified by ORBi

Olivier, S., Close, P., Castermans, E., de Leval, L., Tabruyn, S., Chariot, A., Malaise, M., Merville, M.-P., Bours, V., & Franchimont, N. (May 2006). Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Molecular Pharmacology, 69 (5), 1615-1623. doi:10.1124/mol.105.020479
Peer Reviewed verified by ORBi

Cornet, A., Nguyen, N.-Q.-N., Lion, M., Tabruyn, S., Sabatel, C., Kinet, V., Noël, A., Beckers, M.-C., Struman, I., & Martial, J. (May 2006). Molecular profiling of 16K PRL treated tumours by an antibody-array approach [Poster presentation]. Bioforum, Liège, Belgium.

Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Adenovirus-mediated gene transfer of 16K prolactin inhibits B16-F10 tumor growth and metastasis [Poster presentation]. Bioforum, Liège, Belgium.

Nguyen, N.-Q.-N., Cornet, A., Tabruyn, S., Rentier-Delrue, F., Noël, A., Martial, J., & Struman, I. (2006). Evaluation of 16K Prolactin to prevent metastatic spread through inhibition of angiogenesis [Poster presentation]. Gordon Research Conference: Prolactin Family, Ventura, United States - California.

Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Lair, F., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103 (39), 14319-14324. doi:10.1073/pnas.0606638103
Peer Reviewed verified by ORBi

Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Tilted peptides of PRL/GH family and their potential role in angiogenesis [Poster presentation]. Bioforum, Liège, Belgium.

Tabruyn, S., Nguyen, N.-Q.-N., Cornet, A., Martial, J., & Struman, I. (July 2005). The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G(0)-G(1) and the G(2)-M phases. Molecular Endocrinology, 19 (7), 1932-1942. doi:10.1210/me.2004-0515
Peer Reviewed verified by ORBi

Piwnica, D., Touraine, P., Struman, I., Tabruyn, S., Bolbach, G., Clapp, C., Martial, J., Kelly, P. A., & Goffin, V. (October 2004). Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance. Molecular Endocrinology, 18 (10), 2522-2542. doi:10.1210/me.2004-0200
Peer Reviewed verified by ORBi

Tabruyn, S., Sorlet, C. M., Rentier-Delrue, F., Bours, V., Weiner, R. I., Martial, J., & Struman, I. (September 2003). The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappa B. Molecular Endocrinology, 17 (9), 1815-1823. doi:10.1210/me.2003-0132
Peer Reviewed verified by ORBi

Tabruyn, S., Sorlet, C., Georges, A., Rentier-Delrue, F., Martial, J., & Struman, I. (2003). 16K hPRL prevents angiogenesis by inducing both apoptosis and cell cycle arrest of endothelial cells [Poster presentation]. Euroconférences: Angiogenesis 2, Paris, France.

Contact ORBi